

Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: <a href="mailto:info@nglfinechem.com">info@nglfinechem.com</a> CIN L24110MH1981PLC025884, Website www.nglfinechem.com

August 4, 2023

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai — 400 001.

To, Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No.C/1, G Block, Bandra Kurla Complex, Bandra East, Mumbai 400050.

Sub: Outcome of the Board Meeting Dated 4th August, 2023.
Scrip Code: 524774 Symbol: NGLFINE

Dear Sir/Madam,

This is to inform you that the second Meeting of the Board of Directors of NGL Fine-Chem Limited for the Financial Year 2023-2024 held on Friday, 4th August, 2023 at 301 E-Square, Subhash Road, Vile Parle East, Mumbai 400057 approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended 30th June, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Report issued by the Statutory Auditors of the Company.

The aforesaid results are also being disseminated on Company's website at www.nglfinechem.com.

The meeting of the Board of Directors commenced at 5.30 p.m. and concluded at 6.50 p.m.

Kindly take the same on your record.

Thanking you,

Yours faithfully, For NGL Fine-Chem Limited

Pallavi Satish Digitally signed by Pallavi Satish Pednekar Date: 2023.08.04
19:02:36 +05'30'

Pallavi Pednekar Company Secretary & Compliance Officer Membership No: A33498

# **NGL FINE-CHEM LIMITED**

Regd Office: 301 E Square, Subhash Road, Vile Parle ( East), Mumbai 400 057, Maharashtra, India

CIN: L24110MH1981PLC025884

JNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2023

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2023



(1.06)789.88 (720.00)72.95 (10.95)(8.19)2,003.68 2,328.83 119.72 2.76 308.90 7,284.93 25,606.50 22,243.13 Rupees in lakhs 27,947.58 318.90 28,266.48 11,657,67 3,425.47 2,659.98 2,659.98 2,011.87 Year ended 31.03.2023 72.05 51.19 2.38 44.12 308.90 826.68 49.80 195.78 66.64 (87.50)(7.07)N.A 368.04 66.64 300.70 6,658.45 3,124.25 2,027.26 6,357.75 6,591.81 30.06.2022 (0.70) 2.10 855.07 145.26 919.36 191.72 39.74 308.90 7,562.74 664.71 32.25 6,454.51 1,108.23 1,108.23 295.00) 852.97 A.N 7,417.48 2,757.01 .889.46 Quarter endec 31.03.2023 (Audited) (17.16)(23.16)186.00) (30.95) 67.62 757.40 308.90 380.23 7,291.58 165.38 979.39 24.29 199.89 916.10 916.10 780.56 7.79 6,911.35 3,153.70 .852.83 6,375.48 N.A (Unaudited) 30.06.2023 Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each) a. Gain/(Loss) on actuarial valuation of post employment benefits Reserves excluding Revaluation Reserve as per balance sheet of Profit (Loss) for the period from continuing operations (VII-VIII) b) (Increase)/Decrease in stock in trade and work in progress Profit/(loss) before exceptional items and tax (III-IV) c. Other Comprehensive Income (Net of Tax) e) Depreciation and amortisation expenses Particulars c) Employee benefits expenses a) Cost of Material Consumed Profit/(loss) Before Tax (V-VI) Other Comprehensive Income Total Comprehensive Income Revenue from Operations b. Deferred tax on above Total Revenue (I+II) Total Expenses (IV) f) Other expenses Exceptional Items d) Finance Costs c) Deffered Tax a) Current Tax Other Income b) Prior Years Tax Expense b) MAT Tax Expenses: ΞX 5 5 = × Ξ × Ξ (10.53)(8.39) 110.70 50.96 308.90 28,250.41 119.72 (727.00)(11.21)2.82 2,041.24 Rupees in lakhs 28,361.11 11,640.72 2,391.35 3,687.35 1,129.11 6,656.64 25,624.90 2,736.20 2,736.20 2,049.63 21,946.01 Year ended 31.03.2023 (Audited) (87.50) (7.26) 250.09 889.98 49.80 360.49 85.18 6,525.00 6,775.09 426.15 .896.29 6,721.00 54.09 54.09 2.39 44.51 308.90 Y. 3,098.29 51.77 (Unaudited) 30.06.2022 (6.16) (0.70) 724.48 990.57 33.92 267.93 6,393.73 32.98 932.49 2.09 934.58 308.90 7,512.54 86.66 7,599.20 .599.82 1,205.47 (299.80)2,777.01 ,205.47 Quarter ender 31.03.2023 (Audited) 144.89 24.29 285.85 67.62 (20.33) (23.40)827.29 ,060.87 205.00) 850.69 308.90 7,104.21 332.16 7,436.37 1,008.40 1,008.40 7.88 .664.31 6,427.97 (Unaudited) 30.06.2023 Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each) a. Gain/(Loss) on actuarial valuation of post employment benefits Reserves excluding Revaluation Reserve as per balance sheet of Profit (Loss) for the period from continuing operations (VII-VIII) b) (Increase)/Decrease in stock in trade and work in progress Profit/(loss) before exceptional items and tax (III-IV) c. Other Comprehensive Income (Net of Tax) e) Depreciation and amortisation expenses Particulars c) Employee benefits expenses a) Cost of Material Consumed Profit(loss) Before Tax (V-VI) Other Comprehensive Income Total Comprehensive Income Revenue from Operations b. Deferred tax on above Total Revenue (I+II) Fotal Expenses (IV) f) Other expenses Exceptional Items d) Deffered Tax Other Income a) Current Tax c) Prior Years Tax Expense b) MAT Tax Expenses: **≡**X ≡ ₹ \ × 5 × ₹

Notes:

a) Basic b) Diluted

Earnings Per Share (EPS)

≥

- The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday, 4th Aug, 2023. These results were subjected to Limited Review by the Statutory Auditors of the Company.
- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2016 (IndAS prescribed under Section 133 of the Companies Act 2013 and read with the rules framed thereunder) and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time
- 3 The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
  - The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polychem Private Limited.
- The figures for the quarter ended March 31, 2023 are the balancing figures between the audited figures in respect of the full year ended March 31, 2023 and the published year to date figures upto the the third quarter ended December 31, 2022 of the relevant financial year
- b. Previous period figures have been regrouped/rearranged wherever necessary.

# Notes:

b) Diluted

33.18

15.09

13.77

13.77

15.09

33.18

0.84

previous accounting year Earnings Per Share (EPS)

≥×

The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 4th August, 2023. These results were subjected to Limited Review by the Statutory Auditors of the Company.

32.56

32.56

0.83

13.81

13.81

12.63

- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (IndAS prescribed under Section 133 of the Companies Act 2013 and read with the rules framed thereunder) and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time
- The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
  - Previous period figures have been regrouped/rearranged wherever necessary.
- The figures for the quarter ended March 31, 2023 are the balancing figures between the audited figures in respect of the full year ended March 31, 2023 and the published year to date figures upto the the third quarter ended December 31, 2022 of the relevant financial year

for and On behalf of Board of Directors

DIN 00223346

Place: Mumbai Date: 4th August 2023



### MANEK & ASSOCIATES

**CHARTERED ACCOUNTANTS** 

Offi. # 4600 7525 # 2618 5110 shailesh.manek@gmail.com shailesh@camanek.com www.camanek.com

A-102, Universal Paradise, Nanda Patkar Road, Vile Parle (East), Mumbai - 400 057.

SHAILESH MANEK B.Com.(Hons), Grad. C.W.A.,F.C.A. Cell: +91 93222 26311 MITTUL B. DALAL B.Com. A.C.A Ceil: +91 80973 74277

Review report to
The Board of Directors,
M/s.NGL Fine-Chem Limited

We have reviewed the accompanying statement of unaudited financial results of M/s.NGL Fine-Chem Limited for the period ended June 30, 2023.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MANEK AND ASSOCIATES Chartered Accountants

Firm's Registration No.:126679W

MUMBAI

Dated: 04/08/2023

(SHAILESH MANEK)

Partner

Membership Number:034925 UDIN: 23034925BGXJRT6636



### MANEK & ASSOCIATES

#### **CHARTERED ACCOUNTANTS**

A-102, Universal Paradise, Nanda Patkar Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 4600 7525 # 2618 5110 shailesh.manek@gmail.com shailesh@camanek.com www.camanek.com

SHAILESH MANEK B.Com.(Hons), Grad. C.W.A.,F.C.A. Cell: +91 93222 26311 MITTUL B. DALAL B.Com. A.C.A Ceil: +91 80973 74277

#### **Independent Auditor's Review Report**

To,
The Board of Directors,
M/s.NGL Fine-Chem Limited

- 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of M/s.NGL Fine-Chem Limited ("the Parent") and its subsidiary M/s.Macrotech Polychem Private Limited (the Parent and its subsidiary together referred to as "the Group", and its share of the net profit/loss) after tax and total comprehensive income/loss of its associates and joint ventures for the quarter ended June 30, 2023 and for the period from 01st April 2023 to 30th June 2023 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

## MANEK & ASSOCIATES

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the result of M/s.Macrotech Polychem Private Limited, its wholly owned subsidiary.
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MANEK & ASSOCIATES Chartered Accountants

Firm's Registration No.:126679W

MUMBAI

Dated: 04/08/2023

(SHAILESH MANEK)

Partner

Membership Number:034925 UDIN: 23034925BGXJRU3318